Sparsentan for proteinuria from VEGF inhibitor cancer treatment
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if sparsentan can reduce high levels of protein in the urine caused by VEGF signaling pathway inhibitors (VSPIs), a type of cancer treatment. It may help protect kidney function during cancer therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have active cancer
- You are currently taking a VEGF inhibitor (VSPI) and have new high protein in your urine (2+ on a dipstick or higher)
- Your kidney function (eGFR) is 45 mL/min or above
- You have not had high protein in your urine before starting VSPI treatment
- You do not have serious heart disease (like heart failure or recent heart attack/stroke), liver problems, or other conditions on the exclusion list
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
This study is collecting information from people in Switzerland who are already taking the drug sparsentan for IgA nephropathy, a kidney disease. Doctors want to learn more about how well the treatment works in everyday care, which may help improve future care for others.
This trial tests a new medication called survodutide to see if it can reduce protein in the urine and protect kidney function in people with chronic kidney disease. It may be an option for people who already take standard blood pressure and kidney-protecting pills.
This trial tests if the drug finerenone can help children with IgA vasculitis (HSP nephritis) who have mild protein in their urine. It aims to protect kidney function without using stronger medications like steroids.
This trial tests a medication called atrasentan to see if it helps protect kidney function in people with IgA nephropathy, a kidney disease. It may slow down kidney damage and reduce protein in the urine.
Hear when a new Proteinuric Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.